# Protective Effect of Aspirin on COVID-19 Patients

> **NCT04365309** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Xijing Hospital** · enrollment: 128 (estimated)

## Conditions studied

- Novel Coronavirus Pneumonia
- Aspirin
- Treatment

## Interventions

- **DRUG:** Aspirin 100mg

## Key facts

- **NCT ID:** NCT04365309
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-10
- **Primary completion:** 2020-04
- **Final completion:** 2020-06
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2020-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04365309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04365309, "Protective Effect of Aspirin on COVID-19 Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04365309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*